Skip to main content
Premium Trial:

Request an Annual Quote

RXi Obtains Three-Year Option to License UMMS Therapeutic RNAi IP

NEW YORK (GenomeWeb News) - RXi Pharmaceuticals has signed a three-year agreement with the University of Massachusetts Medical School that will allow the company to license all unrestricted therapeutic RNAi technology the school develops during that period, RXi parent company CytRx said today.
RXi said it licensed the UMMS technology for a combination of "cash and equity." Details of the financial terms were not provided.
The company said UMMS has disclosed new, unrestricted RNAi technologies, and that the agreement gives it the right to negotiate “on an exclusive basis" with UMMS to obtain a license for worldwide use of the technology "on commercially reasonable terms."
The option rights depend upon RXi's receipt of working capital funding in the coming months, the company added.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.